Eliem Therapeutics, Inc. (ELYM)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 8.69 |
| Open | 8.63 |
| Bid | 8.65 x 100 |
| Ask | 9.12 x 100 |
| Day's range | 8.52 - 9.25 |
| 52-week range | 2.34 - 11.55 |
| Volume | |
| Avg. volume | 896,339 |
| Market cap | 262.118M |
| Beta (5Y monthly) | -0.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Benzinga
Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal
Eliem Therapeutics Inc (NASDAQ:ELYM) has agreed to acquire Tenet Medicines Inc., a development-stage private biotechnology company. The combined company plans to focus on advancing TNT119, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. In June 2023, Eliem Therapeutics completed a review of its business, including the status of its programs, resources, and capabilities. The compa
- Simply Wall St.
Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Simply Wall St.
Eliem Therapeutics (NASDAQ:ELYM) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
© 2024 Yahoo. All rights reserved.